Preclinical models effective in studying molecular mechanisms by which estrogen stimulates tumor proliferation and development of endocrine resistance in ER + breast cancer have concluded that the cross talk between growth factors might be significant in development of resistance to therapy [26]. The gene discussed is ESR1; the disease is breast carcinoma.